drugset / Trial / NCT02456558

Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects

NCT02456558

Phase 1 Completed 30 enrolled ApoPharma
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety, tolerability, antiretroviral activity, pharmacokinetics, and pharmacodynamics of an intravenous formulation of deferiprone in HIV-infected subjects.

Timeline

Start
2015-06
Primary completion
2016-03
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferiprone Small molecule 1.5 g Intravenous
Subject Deferiprone Small molecule 2 g Intravenous

Indications

No indication recorded.